Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of PPI-668 Tablet vs Capsule in Healthy Volunteers
NCT02258321Phase 1Completed
- Sponsor
- Presidio Pharmaceuticals
- Start
- Oct 2014
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ravidasvir in hepatitis C (HCV) (2 arms), sponsored by Presidio Pharmaceuticals. Primary endpoints: Area Under the Curve from Time Zero to Infinity, Maximum Observed Plasma Concentration and 1 more. Started Oct 2014; status: completed.
02
Drugs
ravidasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02258321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02258321.